DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis – data from two Central European countriesECCO'16 DOP 2016
1
DOP032: 28Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safeECCO'16 DOP 2016
1
DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn’s disease: results from a real-life population-based cohortECCO'16 DOP 2016
1
DOP035: Longterm outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα –blocking agentsECCO'16 DOP 2016
1
DOP037: Excess steroid use in IBD: too much, how much and why? Results from a UK nationwide auditECCO'16 DOP 2016
1
DOP038: Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitisECCO'16 DOP 2016
1
DOP039: Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with inflammatory bowel disease (IBD)ECCO'16 DOP 2016
1
DOP040: Effects of education and information on vaccination behavior in IBD patientsECCO'16 DOP 2016
1
DOP041: Impact of an education program on IBD patient's skills: one year results of the ECIPE randomized, controlled multicenter study.ECCO'16 DOP 2016
1
DOP043: Non-adherence to anti-TNF therapy predicts clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre studyECCO'16 DOP 2016
1
DOP045: Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel DiseaseECCO'16 DOP 2016
1
DOP046: Mid- to Long-term Stability and Associated Prognostic Factors of Adalimumab Treatment for 1189 Patients with Crohn’s Disease: A Multicenter Cohort StudyECCO'16 DOP 2016
1
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 7ECCO'16 DOP 2016
1